Impact of Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study

被引：0

作者：

Kumada, Naotaka ^{[1
,2
]}

Iinuma, Koji ^{[1
]}

Kubota, Yasuaki ^{[3
]}

Takagi, Kimiaki ^{[4
]}

Nakano, Masahiro ^{[5
]}

Ishida, Takashi ^{[6
]}

Yokoi, Shigeaki ^{[7
]}

Sugino, Fumiya ^{[1
]}

Kawase, Makoto ^{[1
]}

Takeuchi, Shinichi ^{[1
]}

Kawase, Kota ^{[1
]}

Kato, Daiki ^{[1
]}

Takai, Manabu ^{[1
]}

Tobisawa, Yuki ^{[1
]}

Ito, Takayasu ^{[8
]}

Nakane, Keita ^{[1
]}

Koie, Takuya ^{[1
]}

机构：

[1] Gifu Univ, Grad Sch Med, Dept Urol, Yanagido 1-1, Gifu 5011194, Japan

[2] Matsunami Gen Hosp, Dept Urol, 185-1 Kasamatsucho, Gifu 5016062, Japan

[3] Toyota Mem Hosp, Dept Urol, 1-1 Heiwacho, Toyota 4718513, Japan

[4] Daiyukai Hosp, Dept Urol, 1-9-9 Sakura, Ichinomiya 4918551, Japan

[5] Gifu Prefectural Gen Med Ctr, Dept Urol, 4-6-1 Noisiki, Gifu 5008717, Japan

[6] Gifu Municipal Hosp, Dept Urol, 7-1 Kashimacho, Gifu 5008513, Japan

[7] Cent Japan Int Med Ctr, Dept Urol, Minokamo 5058510, Japan

[8] Gifu Univ, Grad Sch Med, Ctr Clin Training & Career Dev, Gifu 5011194, Japan

来源：

DISEASES | 2024年 / 12卷 / 06期

基金：

日本学术振兴会;

关键词：

metastatic renal cell carcinoma; cytoreductive nephrectomy; immune checkpoint inhibitors; targeted therapy; immune checkpoint inhibitors-based combination therapy; TARGETED THERAPY; PLANNED NEPHRECTOMY; SUNITINIB; EFFICACY; CRITERIA;

D O I：

10.3390/diseases12060122

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

In this study, we aimed to determine the utility of cytoreductive nephrectomy (CN) in real-world clinical practice and investigate whether CN contributes to improved oncological outcomes in patients with metastatic renal cell carcinoma (mRCC). This retrospective multicenter cohort study enrolled patients with mRCC who received systemic therapy at six institutions between May 2005 and May 2023. The patients were divided into those who did not undergo CN (Group I) and those who underwent CN (Group II). The primary endpoints were oncological outcomes, including cancer-specific survival (CSS) and progression-free survival (PFS). Altogether, 137 patients with mRCC were included in this study. The median CSS was 14 months in Group I and 32 months in Group II (p < 0.001). Additionally, the median PFS in Groups I and II was 5 and 13 months, respectively (p = 0.006). A multivariate analysis showed that CN was an independent prognostic factor for CSS and PFS. Hence, CN is a potential treatment modality that can improve oncological outcomes in patients with mRCC.

引用

页数：16

共 45 条

[1] Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium
Bakouny, Ziad
El Zarif, Talal
Dudani, Shaan
Wells, J. Connor
Gan, Chun Loo
Donskov, Frede
Shapiro, Julia
Davis, Ian D.
Parnis, Francis
Ravi, Praful
Steinharter, John A.
Agarwal, Neeraj
Alva, Ajjai
Wood, Lori
Kapoor, Anil
Morales, Jose M. Ruiz
Kollmannsberger, Christian
Beuselinck, Benoit
Xie, Wanling
Heng, Daniel Y. C.
Choueiri, Toni K.
[J]. EUROPEAN UROLOGY, 2023, 83 (02) : 145 - 151
[2] Bex A, 2019, JAMA ONCOL, V5, P164, DOI 10.1001/jamaoncol.2018.5543
[3] Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma
Bhindi, Bimal
Graham, Jeffrey
Wells, J. Connor
Bakouny, Ziad
Donskov, Frede
Fraccon, Anna
Pasini, Felice
Lee, Jae Lyun
Basappa, Naveen S.
Hansen, Aaron
Kollmannsberger, Christian K.
Kanesvaran, Ravindran
Yuasa, Takeshi
Ernst, D. Scott
Srinivas, Sandy
Rini, Brian, I
Bowman, Isaac
Pal, Sumanta K.
Choueiri, Toni K.
Heng, Daniel Y. C.
[J]. EUROPEAN UROLOGY, 2020, 78 (04) : 615 - 623
[4] Bhindi B, 2019, EUR UROL, V75, P111, DOI [10.1016/j.eururo.2018.11.021, 10.1016/j.eururo.2018.09.016]
[5] Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma
Bhindi, Bimal
Habermann, Elizabeth B.
Mason, Ross J.
Costello, Brian A.
Pagliaro, Lance C.
Thompson, R. Houston
Leibovich, Bradley C.
Boorjian, Stephen A.
[J]. JOURNAL OF UROLOGY, 2018, 200 (03) : 528 - 534
[6] Renal cell carcinoma: the population, real world, and cost-of-illness
Buja, Alessandra
De Luca, Giuseppe
Gatti, Maura
Cozzolino, Claudia
Rugge, Massimo
Zorzi, Manuel
Gardi, Mario
Sepulcri, Matteo
Bimbatti, Davide
Baldo, Vincenzo
Maruzzo, Marco
Basso, Umberto
Zagonel, Vittorina
[J]. BMC UROLOGY, 2022, 22 (01)
[7] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K.
Powles, T.
Burotto, M.
Escudier, B.
Bourlon, M. T.
Zurawski, B.
Juarez, V. M. Oyervides
Hsieh, J. J.
Basso, U.
Shah, A. Y.
Suarez, C.
Hamzaj, A.
Goh, J. C.
Barrios, C.
Richardet, M.
Porta, C.
Kowalyszyn, R.
Feregrino, J. P.
Zolnierek, J.
Pook, D.
Kessler, E. R.
Tomita, Y.
Mizuno, R.
Bedke, J.
Zhang, J.
Maurer, M. A.
Simsek, B.
Ejzykowicz, F.
Schwab, G. M.
Apolo, A. B.
Motzer, R. J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) : 829 - 841
[8] Choueiri TK, 2020, ANN ONCOL, V31, P1030, DOI [10.1016/j.annonc.2020.04.010, 10.1016/j.annoc.2020.04.010]
[9] The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies
Claeys, Tom
Lumen, Nicolaas
Kumps, Candy
Praet, Marleen
De Meerleer, Gert
Rottey, Sylvie
Ost, Piet
Devisschere, Pieter
Villeirs, Geert
Fonteyne, Valerie
Decaestecker, Karel
[J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (04) : 152.e13 - 152.e22
[10] Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data
de Bruijn, Roderick
Wimalasingham, Akhila
Szabados, Bernadett
Stewart, Grant D.
Welsh, Sarah J.
Kuusk, Teele
Blank, Christian
Haanen, John
Klatte, Tobias
Staehler, Michael
Powles, Thomas
Bex, Axel
[J]. EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (02): : 168 - 173

← 1 2 3 4 5 →